28 Pilot Study of Sirolimus in Cirrhotic Patients With Advanced Hepatocellular Carcinoma

Decaens, Thomas; Luciani, Alain; Itti, Emmanuel; Hulin, Anne; Hurtova, Monika; Laurent, Alexis; Cherqui, Daniel; Mallat, Ariane; Duvoux, C.

doi:10.1016/s0168-8278(08)60030-6

Cited by 12 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…mTOR inhibitors. Rapamycin (sirolimus) and its analogs (temsirolimus and everolimus) are agents blocking the mTOR signaling cascade and have been tested in preclinical and early clinical investigations [328]. Everolimus, an mTOR blocker approved for kidney cancer therapy, is being tested in phase III for a secondline indication.…”

Section: Sorafenibmentioning

confidence: 99%

EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

2012

Journal of Hepatology

4,743

2,339

View full text Add to dashboard Cite

Section: Sorafenibmentioning

confidence: 99%

EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

2012

Journal of Hepatology

4,743

2,339

View full text Add to dashboard Cite

“…No major sirolimus‐related side effects were observed in this study (75). In the French pilot study, 14 patients were treated with 30 mg oral sirolimus once a week (76). A complete or a partial response according to the RECIST criteria was observed in 7 and 33% of patients respectively.…”

Section: Mtor Inhibitorsmentioning

confidence: 99%

“…Sirolimus also seemed to be safe because no grade 4 toxicity was observed and only two patients experienced grade 3 mucositis. Sirolimus did not affect liver function (76). Several phase I and phase II studies are currently testing mTOR inhibitors as single agents (NCT00390195 and NCT00516165), in combination with sorafenib (NCT01008917) or with bevacizumab (NTC00775073).…”

Section: Mtor Inhibitorsmentioning

confidence: 99%

“…Around 30% of HCCs overexpress the IGF-1R. Preclinical studies suggest that inhibition of the IGF receptors suppresses HCC cell growth (69)(70)(71)(72)(73)(74)(75)(76)(77)(78)(79)(80)(81)(82)(83)(84). Small molecules and monoclonal antibodies targeting IGF-1R (such as the monoclonal antibody A12, cixutumumab and AVE 1642) are under early clinical development.…”

Section: Insulin Growth Factor 1 Receptor Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

Novel molecular therapies in hepatocellular carcinoma

Faivre

Bouattour

Raymond

2011

Liver International

View full text Add to dashboard Cite

The approval of sorafenib as the standard of care (SOC) for advanced hepatocellular carcinoma (HCC) fostered interest to further evaluate several other targeted therapies and extend the positioning of sorafenib alone and in combination with other drugs and local therapies at earlier stages and in an adjuvant setting. This review highlights current research using targeted therapies in HCC. Information for this review was compiled by searching PubMed and MEDLINE databases for articles published until September 2010. Several small molecules and humanized antibodies with anti-angiogenic and antiproliferative properties are currently being investigated in preclinical and/or clinical trials. Results are awaited from these clinical trials and offer promise for extending the current treatment options in HCC. Currently published data suggest that substantial progress may be achieved in the treatment of patients with HCC in the next 10 years.

show abstract

“…Récemment, une étude pilote a montré des résultats prometteurs dans le traitement des CHC localement avancés sur foie cirrhotique par du sirolimus 30 mg/s jusqu'à progression. Le taux objectif de réponse était de 40 % avec, sur un effectif de 14 patients, une réponse complète et quatre réponses partielles [26]. Des résultats intéressants ont également été publiés en phase II dans le traitement des tumeurs endocrines par évérolimus.…”

Section: Efficacité Sur D'autres Tumeursunclassified